| Entry |
|
|---|
| Name |
Fulvestrant (JAN/USP/INN);
Faslodex (TN) |
|---|
| Product |
|
|---|
| Generic |
FULVESTRANT (Accord Healthcare), FULVESTRANT (Amneal Pharmaceuticals LLC), FULVESTRANT (AstraZeneca Pharmaceuticals LP), FULVESTRANT (Athenex Pharmaceutical Division), FULVESTRANT (BluePoint Laboratories), FULVESTRANT (Chia Tai Tianqing Pharmaceutical Group), FULVESTRANT (Dr.Reddy's Laboratories), FULVESTRANT (EBEWE Pharma Ges.m.b.H. Nfg.KG), FULVESTRANT (GLENMARK PHARMACEUTICALS), FULVESTRANT (HBT Labs), FULVESTRANT (Meitheal Pharmaceuticals), FULVESTRANT (Mylan Institutional LLC), FULVESTRANT (NorthStar Rx LLC), FULVESTRANT (Northstar RxLLC), FULVESTRANT (Sagent Pharmaceuticals), FULVESTRANT (Sandoz), FULVESTRANT (Sandoz) |
|---|
| Formula |
C32H47F5O3S
|
|---|
| Exact mass |
606.3166
|
|---|
| Mol weight |
606.7708
|
|---|
| Structure |
|
|---|
| Class |
Antineoplastic
DG01585 Estrogen receptor antagonist
Metabolizing enzyme substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Therapeutic category: | 4291 |
|
|---|
| Efficacy |
Antineoplastic, Estrogen receptor agonist/antagonist |
|---|
| Disease |
Breast cancer, postmenopausal (HR positive) [DS: H00031] Breast cancer, postmenopausal (HR positive, HER2 negative) [DS: H00031] |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07226 | Progesterone, androgen and estrogen receptor agonists/antagonists |
|
|---|
| Other map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L02 ENDOCRINE THERAPY
L02B HORMONE ANTAGONISTS AND RELATED AGENTS
L02BA Anti-estrogens
L02BA03 Fulvestrant
D01161 Fulvestrant (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Antiestrogens/Modifiers
Fulvestrant
D01161 Fulvestrant (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D01161 Fulvestrant (JAN/USP/INN)
Target-based classification of drugs [BR:br08310]
Nuclear receptors
Estrogen like receptors
Estrogen receptor
NR3A (ESR)
D01161 Fulvestrant (JAN/USP/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01161
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D01161
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01161
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01161
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D01161
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D01161
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 41
1 C8x C 7.4203 -16.5528
2 C8y C 7.4203 -17.9330
3 C8x C 8.6185 -18.6231
4 C8x C 8.6185 -15.8628
5 C8y C 9.8096 -16.5528
6 C8y C 9.8037 -17.9330
7 C1x C 10.9960 -18.6281
8 C1y C 12.1942 -17.9432
9 C1y C 11.0077 -15.8679
10 C1y C 12.1942 -16.5658
11 C1x C 12.2169 -13.8129
12 C1x C 11.0191 -14.4913
13 C1z C 13.4035 -14.5109
14 C1y C 13.3866 -15.8831
15 C1x C 15.7638 -15.9121
16 C1x C 15.7803 -14.5396
17 C1y C 14.6003 -13.8392
18 O1a O 14.7331 -12.4541
19 O1a O 6.2253 -18.6237
20 C1b C 13.3801 -18.6301
21 C1b C 14.5721 -17.9469
22 C1b C 15.7641 -18.6370
23 C1b C 16.9561 -17.9539
24 C1b C 18.1480 -18.6440
25 C1b C 19.3400 -17.9609
26 C1b C 20.5319 -18.6510
27 C1b C 21.7239 -17.9678
28 C1b C 22.9159 -18.6579
29 S4a S 24.1078 -17.9748
30 C1b C 25.2998 -18.6649
31 C1b C 26.4917 -17.9819
32 C1b C 27.6837 -18.6720
33 C1d C 28.8756 -17.9887
34 O3c O 24.1108 -16.5946
35 X F 29.9914 -17.2156
36 X F 27.8928 -17.0058
37 C1a C 13.3941 -13.1303
38 C1d C 29.8649 -18.9778
39 X F 30.8541 -19.9671
40 X F 31.0764 -18.2784
41 X F 28.6534 -19.6773
BOND 44
1 4 1 1
2 2 19 1
3 1 2 2
4 8 20 1 #Down
5 9 10 1
6 20 21 1
7 10 14 1
8 21 22 1
9 13 11 1
10 22 23 1
11 11 12 1
12 23 24 1
13 12 9 1
14 24 25 1
15 2 3 1
16 25 26 1
17 3 6 2
18 26 27 1
19 5 6 1
20 27 28 1
21 6 7 1
22 28 29 1
23 7 8 1
24 29 30 1
25 13 14 1
26 30 31 1
27 15 16 1
28 31 32 1
29 16 17 1
30 32 33 1
31 17 13 1
32 29 34 2
33 14 15 1
34 8 10 1
35 17 18 1 #Up
36 9 5 1
37 33 35 1
38 5 4 2
39 33 36 1
40 13 37 1 #Up
41 33 38 1
42 38 39 1
43 38 40 1
44 38 41 1
|
|---|
